Characteristic | Group Aa (n = 17) | Group Ba (n = 34) |
---|---|---|
Age (years) (mean, range) | 37, 23–52 | 36.7, 14–70 |
Sex (males/females) | 3/14 | 4/30 |
Disease duration (years) (mean, range) | 9.6, 0.5–21 | 10, 0.5–24 |
SLEDAI (mean ± SD) | 5.0 ± 5.5 | 5.1 ± 7.5 |
Neurological manifestations [no. (%)] | 5 (29.4) | 13 (38.2) |
Cutaneous manifestations [no. (%)] | 13 (76.5) | 21 (61.8) |
Arthritis [no. (%)] | 14 (82.3) | 23 (67.6) |
Renal manifestations [no. (%)] | 2 (11.8) | 12 (35.3) |
Cytopenia [no. (%)] | 12 (70.6) | 20 (58.8) |
Serositis [no. (%)] | 4 (23.5) | 10 (29.4) |
Prednisone [no. (%); mean mg/day] | 12 (70.6); 10.0 | 28 (82.3); 12.3 |
Hydroxychloroquine [no. (%)] | 5 (29.4) | 16 (47) |
Azathioprine [no. (%)] | 4 (23.5) | 8 (23.5) |
Methotrexate [no. (%)] | 2 (11.8) | 2 (5.9) |
Cyclosporin A [no. (%)] | 3 (17.6) | 4 (11.8) |
Cyclophosphamide [no. (%)] | none | 3 (8.8) |